Dr. Reddy’s Laboratories RDY reported first-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 58 cents, up 13.7% from the year-ago quarter.
The company reported revenues of $591 million during the quarter, up 6.9% from the year-ago quarter. The company’s shares gained 5.9% following the announcement.
The Quarter in Detail
Dr. Reddy’s reports revenues under three segments – Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Proprietary Products and Others.
Global Generics revenues grew 7.7% year over year to $487 million, primarily driven by North America, Europe, Venezuela and India.
Revenues from North America were mainly boosted by sustained performance of the injectable franchise and higher market share in key molecules, apart from contributions from Habitrol and the company’s generic version of Valcyte and Rapamune.
Revenues from Europe were driven by the launch of company’s generic version of Abilify and Lyrica during fourth-quarter fiscal 2015.
In emerging markets, sales in Russia suffered from ongoing macroeconomic uncertainties and the consequent depreciation of ruble, while Venezuela delivered strong growth on the back of rising prescription volume. In India, growth was driven by continued focus on new product launches as well as prescription growth.
PSAI revenues were up 1.1% year over year to $88 million. During the quarter, Dr. Reddy’s filed 9 DMFs globally. The cumulative number of DMF filings as of Jun 30, 2015 stands at 747.
Revenues at the Proprietary Products and Others segment increased 14.3% to $16 million.
Research and development expenses increased 13.1% year over year to $69 million driven by planned scale-up in development activities.
Selling, general and administrative expenses amounted to $173 million, up 3% year over year, primarily on account of annual increments and other selling, marketing and professional expenses.
During the quarter, Dr. Reddy’s acquired UCB UCBJF established products business in India. Additionally, the company is actively working approval for generic versions of various drugs. In Jul 2015, the company launched its therapeutic equivalent generic version of Allergan’s AGN Namenda in the U.S.
Second-Quarter Fiscal 2016 Outlook
Dr. Reddy’s expects the benefits from the full integration of UCB’s established products business in India to reflect in its results in the next quarter. However, the company anticipates the ongoing macroeconomic uncertainties in Russia and other territories in emerging markets to impact top-line growth, going forward.
Our Take
Dr. Reddy’s first-quarter fiscal 2016 results were encouraging. Moreover, we are pleased with the company’s efforts on increasing its exposure in the U.S. market and gaining FDA approval for new launches. However, persisting macroeconomic issues in some territories in emerging markets and negative impact of the depreciation of ruble remain an overhang.
Meanwhile, we expect investor focus to remain on regulatory updates on DFD-01, DFD-09, and DFN-11, which are currently under review in the U.S.
Dr. Reddy’s currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Progenics Pharmaceuticals, Inc. PGNX, carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment